Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental health market

Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental health market

July 16, 2026Posted inBiotechnology

Eli Lilly has struck a deal to buy AtaiBeckley for $2.8 billion upfront, continuing its takeover spree to move into a psychedelic mental health sector targeted by companies including Johnson & Johnson.

Post navigation

Previous Post
rising-european-dust-pollution-tied-to-a-changing-climate Rising European Dust Pollution Tied to a Changing Climate
Next Post
Sweeteners Slow Growth of Key Gut Bacteria in Laboratory Studies sweeteners-slow-growth-of-key-gut-bacteria-in-laboratory-studies

Recent Posts

  • KPNA2 overexpression worsens T4 colorectal cancer prognosis by nuclear c-Myc suppression of p21
  • Study Links Heavy TV Watching to Smaller Brain Structures
  • UMN researcher wins $3.7 million NIH grant to advance AI glaucoma care
  • Y-Added FeCoNiSiB Amorphous Multi-Principal Alloys Demonstrate Enhanced Performance
  • Wild snapdragons subtly change color to attract bees

Archives

  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top